Cyclopharm CYC.AX · AUD

Its shares trade on ASX under the ticker CYC.AX. It has been listed since 18 January 2007. In the fiscal year to 31 December 2025, it reported revenue of A$32.3m and a net loss of A$17.2m. At that date it held total assets of A$46.1m and shareholders' equity of A$27.1m.

Cyclopharm Ltd. is a radiopharmaceutical company, which engages in the diagnostic imaging in lung health. The company is headquartered in Sydney, New South Wales. The company went IPO on 2007-01-18. The firm operates in two business segments: Technegas segment and Molecular imaging segment. The Technegas segment is a supplier of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. The Molecular Imaging segment produces radiopharmaceuticals used by physicians in the detection of cancer, neurological disorders and cardiac diseases. The firm offers Technegas for lung imaging, and Molecular Imaging/Positron Emission Tomography radiopharmaceuticals, which are used in cancer, brain and cardiac imaging. The firm formed a joint venture with Alfred Health Solutions and Macquarie University Hospital to provide various imaging services on-site at the hospital. The firm's Ultralute is a device that extends the useful life of Molybdenum-99 (Mo-99) generators.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. David HeaneyIndependent Non-Executive Chairman of the BoardA$80,044
• Mr. James McbrayerChief Executive Officer, Managing Director, Executive Director, Company Secretary, since 2008A$849,588
• Mr. Jason SmithChief Financial Officer
• Mr. Mathew FaragChief Operating OfficerA$396,983
• Mr. John WigglesworthNon-Executive Director
• Ms. Dianne AngusNon-Executive Independent DirectorA$57,489
• Mr. Kevin BarrowNon-Executive Independent DirectorA$21,655
• Prof. Dr. Gregory KingNon-Executive Independent DirectorA$15,144

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.